11 July 2023
An analysis of samples obtained from a uniquely designed window-of-opportunity clinical trial (LUD2015-005) has shown that high tumour monocyte content (TMC) is an unexpected predictor of greater overall survival in inoperable oesophageal adenocarcinoma (OAC) patients.
8 June 2023
Team from the Van den Eynde group have discovered that some molecules previously used to treat hypertension might also help the immune system to better fight cancer cells
Ludwig Oxford research wins Journal for ImmunoTherapy of Cancer’s best basic tumour immunology paper of 2022
15 November 2022
A paper on a therapeutic cancer vaccine from the Van den Eynde lab was singled out for this award celebrating excellence in scientific research.
21 October 2022
A collaborative study, led by former Ludwig Oxford group leader Professor Mads Gyrd-Hansen, sheds light on the ZBP1-induced signalling pathway, a pathway which contributes to the viral immune response, including to SARS-CoV-2
15 July 2022
On 13-14th June 2022, the Oxford Branch of the Ludwig Institute for Cancer Research held their annual retreat to discuss key scientific advances within the Branch and beyond.
18 January 2022
A novel immunotherapeutic called VTP-600, based on Ludwig Oxford’s Benoit Van den Eynde’s preclinical research, is being tested in patients for the first time.
3 September 2021
A new publication from Benoit Van den Eynde's group has shown that a viral vector cancer vaccine generates effective anti-tumour immune responses and, in combination with immunotherapy, decreases tumour size and increases survival rates in mouse models.